Mr. Gabriel Fahel reports

HELUS PHARMA TO HOST INVESTOR PRESENTATION ON OCTOBER 21, 2026

Helus Pharma Inc. will host an investor presentation on Oct. 21, 2026.

Discussion topics will include HLP003, the company's proprietary NSA in phase 3 development for the adjunctive treatment of major depressive disorder, and HLP004, its proprietary NSA in phase 2 development for generalized anxiety disorder. The presentation will also include key opinion leaders' perspectives on the current and evolving depression and anxiety treatment landscape, and a question-and-answer session with members of Helus Pharma's executive leadership team.

The live webcast will take place on Wednesday, Oct. 21, 2026, at 9 a.m. EDT. To access the webcast, please visit the events and presentation page of Helus Pharma's website. The archived webcast will be available on the company's website on the events and presentations page following the presentation.

About Helus Pharma Inc.

Helus Pharma is a clinical-stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs, synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The company's proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety and other mental health conditions.

Helus Pharma is working to improve the treatment landscape through the introduction of NSAs that aim to provide durable improvements in mental health. Helus Pharma is currently developing HLP003, a proprietary NSA, in phase 3 clinical development for the adjunctive treatment of MDD that has received breakthrough therapy designation from the U.S. Food and Drug Administration, and HLP004, also a proprietary NSA in phase 2 for GAD. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs.

The company operates in Canada, the United States, the United Kingdom and Ireland.

We seek Safe Harbor.